London startup collects four million dollars to streamline clinical trial setup using software

Preparing a new drug for human trials requires months of bureaucratic navigation, intricate document drafting, and strict compliance checks. When planning mistakes occur, early protocols must be altered, causing lengthy delays before the first patient ever receives a dose. London-based Cori Clinical has gathered $4 million in seed financing to help medical researchers organise that preparation phase more efficiently.

The investment round was led by Breega, with additional backing from Enzo, Heartfelt, Together Ventures, and Bynd. The newly secured money will fund software development, expand technical capacity, and support hiring across engineering, clinical, and commercial teams.

Formed in 2025 by chief executive Jorn Jansen Schoonhoven and chief technology officer Patricio Fernández, the company focuses on the fragmentation that burdens trial design. Medical institutions often keep the lessons learned from earlier studies sequestered in departmental silos or scattered across separate file repositories, making it difficult for planners to spot recurring pitfalls.

Cori addresses this disconnect by assembling a centralised digital workspace. The system pulls institutional records from an organisation's past trials and merges them with public registries and formal guidance published by authorities such as the US Food and Drug Administration, the European Medicines Agency, and the UK Medicines and Healthcare Products Regulatory Agency.

Instead of treating individual forms and clinical documents as isolated tasks, the platform establishes what the founders describe as a living blueprint. This framework links medical hypotheses directly to practical operational schedules, projected expenses, and regulatory submission packets, updating advice as official guidelines evolve.

Early internal performance figures suggest substantial savings in time and expenditure. Company models project that catching protocol flaws prior to submission could cut initial set-up expenses by at least 33 per cent, while retrospective audits against completed studies indicated the software identified 82 per cent of preventable protocol errors.

The company's software has already entered field testing within commercial and academic settings. Two of the world's five largest contract research organisations are testing the system, and researchers at Erasmus MC, a university medical centre in Rotterdam, relied on it to structure clinical trials in neurosurgery and neuro-oncology.

To help guide its next phase of growth, the company recently added Dr Emma Ogburn as chief clinical officer. The founders now intend to broaden their commercial reach among pharmaceutical firms and deepen the clinical rules embedded in the platform.